- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02365493
Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection (CAMERA2)
CAMERA 2 - Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection - An Investigator-initiated, Multi-centre, Parallel Group, Open Labelled Randomised Controlled Trial
The aim of this clinical trial is to determine whether a novel combination antibiotic treatment (vancomycin/daptomycin + beta-lactam) is superior to the standard antibiotic treatment (vancomycin/daptomycin) for hospitalised adults with Methicillin Resistant Staphylococcus aureus bacteraemia. The hypothesis is that the addition of beta-lactam antibiotics (these are antibiotics from the penicillin family) to the standard therapy will lead to more efficient bacterial killing and hence lead to faster clearance of bacteria from the blood stream and other areas of infection, thereby reducing the risk of the spread of infection and death.
The study design is an investigator-initiated, multi-centre, open-label, randomised controlled trial. This will include 440 participants diagnosed with Methicillin Resistant Staphylococcus aureus bacteraemia recruited over a period of 4 years (July 2015 - June 2019) from within Infectious Diseases inpatient units across 21 hospital sites including 18 from within Australia and 3 located in Singapore. Participation will be voluntary and subject to informed consent. The participants will be randomised 1:1 to either the standard therapy group or combination therapy group. The combination therapy will include a treatment of intravenous beta-lactam for the first 7 days of treatment, in addition to the standard treatment (either vancomycin or daptomycin). The primary outcome measure will be complication-free survival 90 days post randomisation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Blacktown, New South Wales, Australia, 2148
- Blacktown Hospital
-
Camperdown, New South Wales, Australia, 2050
- Royal Prince Alfred Hospital
-
Concord, New South Wales, Australia, 2139
- Concord Repatriation General Hospital
-
Darlinghurst, New South Wales, Australia, 2010
- St Vincent's Hospital
-
Kingswood, New South Wales, Australia, 2747
- Nepean Hospital
-
Liverpool, New South Wales, Australia, 2170
- Liverpool Hospital
-
New Lambton Heights, New South Wales, Australia, 2305
- John Hunter Hospital
-
Westmead, New South Wales, Australia, 2145
- Westmead Hospital
-
Wollongong, New South Wales, Australia, 2500
- Wollongong Hospital
-
-
Northern Territory
-
Darwin, Northern Territory, Australia, 0820
- Royal Darwin Hospital
-
-
Queensland
-
Cairns, Queensland, Australia, 4870
- Cairns Hospital
-
Herston, Queensland, Australia, 4029
- Royal Brisbane and Women's Hospital
-
Woolloongabba, Queensland, Australia, 4102
- Princess Alexandra Hospital
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Royal Adelaide Hospital
-
Bedford Park, South Australia, Australia, 5042
- Flinder's Medical Centre
-
Woodville South, South Australia, Australia, 5011
- The Queen Elizabeth Hospital
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Monash Medical Centre Clayton Campus
-
Dandenong, Victoria, Australia, 3175
- Dandenong Hospital
-
Footscray, Victoria, Australia, 3011
- Western Health - Footscray
-
Heidelberg, Victoria, Australia, 3084
- Austin Hospital
-
Sunshine, Victoria, Australia, 3021
- Western Health - Sunshine Hospital
-
Williamstown, Victoria, Australia, 3016
- Western Health - Williamstown Hospital
-
-
Western Australia
-
Murdoch, Western Australia, Australia, 6150
- Fiona Stanley Hospital
-
Perth, Western Australia, Australia, 6000
- Royal Perth Hospital
-
-
-
-
-
Haifa, Israel
- Rambam Health Corporation
-
Petah Tikva, Israel
- Beilinson Hospital
-
-
-
-
Auckland
-
Otahuhu, Auckland, New Zealand, 1640
- Middlemore Hospital
-
-
-
-
-
Kent Ridge, Singapore, 119074
- National University Hospital
-
Outram Park, Singapore, 168753
- Singapore General Hospital
-
-
Tan Tock Seng
-
Novena, Tan Tock Seng, Singapore, 308433
- Tan Tock Seng Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age >= 18 years.
- ≥1 set of blood cultures positive for MRSA
- Able to be randomized within 72 hours of blood cultures being collected.
- Likely to remain as inpatient for 7 days following randomization
Exclusion Criteria:
- Previous type 1 hypersensitivity reaction to ß-lactams
- Polymicrobial bacteraemia (not counting contaminants)
- Previous participation in the trial
- Known pregnancy
- Current β-lactam antibiotic therapy which cannot be ceased or substituted
- Participant's primary clinician unwilling to enrol patient
- Moribund (expected to die in next 48 hours with or without treatment)
- Treatment limitations which preclude the use of antibiotics Note that we are NOT planning to exclude participants with renal failure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard therapy
Intravenous vancomycin dosed as per Australian Therapeutic Guidelines (loading dose of 25 mg/kg followed by maintenance dose of 15-20 mg/kg every 12 hours) with subsequent adjustment to maintain trough levels at 15-20 mg/dL OR Intravenous daptomycin 6-10 mg/kg per day, adjusted for renal function (details of renally adjusted dosing provided in full protocol). The choice of daptomycin or vancomycin is clinician-determined and may be influenced by such factors as local practice, the vancomycin minimum inhibitory concentration (MIC) of the isolate and evidence emerging during the course of the study |
|
Experimental: Standard therapy + Beta-Lactam
In addition to standard treatment an intravenous Beta-Lactam (β-lactam) will be added for the first 7 calendar days following randomisation (randomisation is day 1 - hence patients will receive 6-7 days of β-lactam).
This β-lactam will be intravenous flucloxacillin 2g every 6 hours in Australia and intravenous cloxacillin 2g every 6 hours in Singapore.
For those with a history of minor allergy to any penicillin (rash or unclear history, but not anaphylaxis or angiooedema), it will be intravenous cefazolin 2g every 8 hours.
For haemodialysis patients, it will usually be cefazolin 2g three times per week post dialysis, however clinicians are also free to choose intermittent (flu)cloxacillin, dosed as for glomerular filtration rate (GFR ) <10, if they desire.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complication-free 90 day survival
Time Frame: Time period from randomisation (day 1) to day 90
|
Composite outcome at 90 days - any of:
|
Time period from randomisation (day 1) to day 90
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality at days 14, 42 and 90 days
Time Frame: Time period from randomisation (day 1) to day 90
|
Time period from randomisation (day 1) to day 90
|
|
Persistent bacteraemia at day 2
Time Frame: Time period from randomisation (day 1) to day 90
|
Time period from randomisation (day 1) to day 90
|
|
Persistent bacteraemia at day 5 or beyond
Time Frame: Time period from randomisation (day 1) to day 90
|
Time period from randomisation (day 1) to day 90
|
|
Acute kidney injury defined as ≥ stage 1 modified RIFLE criteria at any time within the first 7 days, OR new need for renal replacement therapy at any time from days 1 to 90. Excludes participants already on haemodialysis.
Time Frame: Time period from randomisation (day 1) to day 90
|
>=stage 1 modified RIFLE criteria (1.5-fold increase in the serum creatinine, or glomerular filtration rate (GFR) decrease by 25 percent).
This endpoint does not apply to participants who were already on haemodialysis at randomisation.
|
Time period from randomisation (day 1) to day 90
|
Microbiological relapse - positive blood culture for MRSA at least 72 hours after a preceding negative culture
Time Frame: Time period from randomisation (day 1) to day 90
|
Time period from randomisation (day 1) to day 90
|
|
Microbiological treatment failure. Positive sterile site culture for MRSA at least 14 days after randomisation
Time Frame: Time period from randomisation (day 1) to day 90
|
Time period from randomisation (day 1) to day 90
|
|
Duration of intravenous antibiotic treatment
Time Frame: Time period from randomisation (day 1) to day 90
|
Time period from randomisation (day 1) to day 90
|
|
Direct health care costs
Time Frame: Time period from randomisation (day 1) to day 90
|
Time period from randomisation (day 1) to day 90
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Joshua Davis, MBBS, FRACP, Menzies School of Health Research
- Principal Investigator: Steven Tong, MBBS, FRACP, Menzies School of Health Research
Publications and helpful links
General Publications
- Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, Archuleta S, Roberts MA, Cass A, Paterson DL, Foo H, Paul M, Guy SD, Tramontana AR, Walls GB, McBride S, Bak N, Ghosh N, Rogers BA, Ralph AP, Davies J, Ferguson PE, Dotel R, McKew GL, Gray TJ, Holmes NE, Smith S, Warner MS, Kalimuddin S, Young BE, Runnegar N, Andresen DN, Anagnostou NA, Johnson SA, Chatfield MD, Cheng AC, Fowler VG Jr, Howden BP, Meagher N, Price DJ, van Hal SJ, O'Sullivan MVN, Davis JS; Australasian Society for Infectious Diseases Clinical Research Network. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal beta-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial. JAMA. 2020 Feb 11;323(6):527-537. doi: 10.1001/jama.2020.0103.
- Tong SY, Nelson J, Paterson DL, Fowler VG Jr, Howden BP, Cheng AC, Chatfield M, Lipman J, Van Hal S, O'Sullivan M, Robinson JO, Yahav D, Lye D, Davis JS; CAMERA2 study group and the Australasian Society for Infectious Diseases Clinical Research Network. CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial. Trials. 2016 Mar 31;17:170. doi: 10.1186/s13063-016-1295-3.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NHMRC1078930
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Methicillin-Resistant Staphylococcus Aureus
-
University of Colorado, DenverAmerican Academy of Family Physicians National Research NetworkCompletedMethicillin-Resistant Staphylococcus AureusUnited States
-
University Hospital, ToulouseCompletedMethicillin-Resistant Staphylococcus AureuS
-
University of Sao PauloUnknownMethicillin Resistant Staphylococcus AureusBrazil
-
University of FloridaRecruitingMethicillin-Resistant Staphylococcus AureusUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedMethicillin-Resistant Staphylococcus AureusFrance
-
University of Lausanne HospitalsCompletedMethicillin-Resistant Staphylococcus Aureus
-
NorthShore University HealthSystemAgency for Healthcare Research and Quality (AHRQ)CompletedMethicillin Resistant Staphylococcus AureusUnited States
-
University of California, IrvineAgency for Healthcare Research and Quality (AHRQ)CompletedMethicillin-Resistant Staphylococcus AureusUnited States
-
Pinyo RattanaumpawanUnknownMethicillin-Resistant Staphylococcus AureusThailand
-
Mercy ResearchWithdrawnMethicillin-Resistant Staphylococcus Aureus
Clinical Trials on Beta-Lactam
-
Chris GossMedical University of South Carolina; University of Washington; Cystic Fibrosis...RecruitingCystic Fibrosis | Cystic Fibrosis Pulmonary ExacerbationUnited States, Canada
-
Hoffmann-La RocheCompletedSoft Tissue InfectionsUnited States, Estonia, Peru, Germany, Bulgaria, South Africa, Latvia, Lithuania, Argentina, Hungary, Romania
-
Qianfoshan HospitalCompletedAcute Kidney Injury | Beta-Lactam Antibiotic Toxicity (Diagnosis)China
-
Hoffmann-La RocheCompletedPneumonia, BacterialUnited States, Romania, Chile, Slovakia, Hungary, Bulgaria, Latvia, Croatia, Peru, Lithuania, Argentina
-
University Hospital, GrenobleNot yet recruitingInfections | Cardiac Arrest | Cardiogenic Shock | Extracorporeal Membrane Oxygenation Complication | Post-cardiac SurgeryFrance
-
Meir Medical CenterCompletedBeta-lactam AllergyIsrael
-
Singapore General HospitalRecruiting
-
Imperial College LondonCompletedPharmacokinetics | Penicillin Allergy | Beta Lactam Adverse ReactionUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisTerminatedUrinary Infection | Digestive Infection | Biliary Infection | Expanded-spectrum Beta-lactamase Producing ESBL
-
Fundación Pública Andaluza para la gestión de la...UnknownComplicated Urinary Tract InfectionSpain